Key Takeaways

• Bacteriostatic Water for Injection, USP is sterile water containing benzyl alcohol as a bacteriostatic preservative. Marketed US product labelling describes either 0.9% (9 mg/mL) or 1.1% (11 mg/mL) benzyl alcohol, at a pH of 5.7 within a specified range of 4.5 to 7.0.
• The preservative is what distinguishes it from Sterile Water for Injection, USP. Benzyl alcohol suppresses microbial proliferation between entries, which is the entire rationale for using a preserved diluent in a multiple-dose vial rather than a single-entry one.
• “Bacteriostatic” describes growth inhibition, not sterilisation. A preserved diluent does not decontaminate a septum, salvage a compromised vial, or substitute for aseptic technique at each entry.
• Benzyl alcohol is not inert toward the solute. Preservatives including benzyl alcohol have been shown in the formulation literature to promote partial unfolding and aggregation of proteins and peptides in aqueous solution, and the magnitude is compound-specific.
• Benzyl alcohol-containing solutions are contraindicated in neonates a restriction that traces to documented benzyl alcohol poisoning in premature infants. Marketed labelling carries an explicit “NOT FOR USE IN NEONATES” warning.
• All peptide material discussed on this page is research-use-only. Nothing here describes a human or veterinary regimen, and concentration arithmetic below is presented as bench preparation of known laboratory solutions.

Laboratories that work with lyophilised peptides spend more time on diluents, vials and septa than the published literature usually admits. The compound arrives as a white cake of a few milligrams, and every measurement made afterwards depends on what it was dissolved in, how it was dissolved, and how the vial was treated between entries. Bacteriostatic water occupies an unusual position in that workflow: it is a pharmacopoeial product with a formal monograph, a regulated label and a well-characterised excipient, yet it is most often discussed informally.

This guide treats it as the pharmaceutical diluent it is. It sets out what bacteriostatic water contains, how it differs from sterile water and from sodium chloride injection, what the preservative does both microbiologically and to the dissolved solute, how reconstitution volume determines the concentration of a lyophilised peptide, and where the common handling errors sit. The register throughout is clinical and procedural on the diluent side, and strictly research-framed on the peptide side.

What Is Bacteriostatic Water?

Bacteriostatic Water for Injection, USP is water for injection to which a bacteriostatic preservative has been added, supplied in a multiple-dose container. In the United States the preservative is benzyl alcohol. Pfizer’s marketed labelling for the product describes a sterile, non-pyrogenic preparation of water for injection containing either 0.9% (9 mg/mL) or 1.1% (11 mg/mL) of benzyl alcohol added as a bacteriostatic preservative, with a pH of 5.7 and a specified range of 4.5 to 7.0. The same labelling states that the solution contains no other antimicrobial agent, bacteriostat, or added buffer, and is intended for use as a diluent or vehicle rather than as a therapeutic fluid in its own right.

Benzyl alcohol itself is a simple aromatic alcohol, C₆H₅CH₂OH, catalogued in PubChem as CID 244. It is one of a small family of excipients, alongside phenol, m-cresol, phenoxyethanol and chlorobutanol, used as antimicrobial preservatives in parenteral products. It is used at low percentage concentrations, is miscible with water, and has a long history in injectable formulation.

Two properties of the finished product matter more than the chemistry of the excipient. The first is that the solution is hypotonic: it contains no solute contributing osmotic pressure. Marketed labelling states that Bacteriostatic Water for Injection must be made approximately isotonic prior to use, and warns that intravenous administration without a solute may result in haemolysis. The second is the presence of the preservative itself, which changes how the container may be handled over time and which brings a defined population restriction with it.

It is worth naming the container format explicitly, because it is the reason the product exists. Sterile Water for Injection is typically supplied in single-dose presentations, and DailyMed labelling for those products frames them as diluent-only, discard-after-use preparations. Bacteriostatic water is supplied as a multiple-dose vial and the preservative is what makes repeated entry into the same container a defensible practice rather than an obvious contamination risk.

How Does Bacteriostatic Water Work?

Benzyl Alcohol as a Bacteriostatic Agent

Benzyl alcohol acts on microbial membranes. As a small amphiphilic molecule it partitions into lipid bilayers, increases membrane fluidity and disrupts the ordered packing that membrane-associated processes depend on. At the concentrations used in preserved parenterals the practical result is inhibition of bacterial and fungal proliferation rather than rapid cidal killing of an established population.

The distinction is not semantic. A bacteriostatic agent holds a small inoculum in check long enough that a vial entered several times over a period of days does not become a growth medium. It does not eliminate an organism introduced in quantity, and it does nothing against bacterial spores. The preservative buys time; it does not buy sterility.

Why the Multiple-Dose Vial Depends on the Preservative

An unpreserved aqueous vehicle punctured repeatedly is a reasonable culture medium at room temperature. The entire logic of the preserved multiple-dose vial is that the fluid remaining in the container after each withdrawal is hostile to the small number of organisms that realistically get introduced by a correctly disinfected septum and a fresh needle.

Institutional infection-prevention guidance reflects this. The CDC’s injection safety guidance for clinicians addresses multiple-dose vials specifically, and the WHO best practices toolkit for injections and related procedures sets out the aseptic sequence that a preserved vial presumes rather than replaces. Neither treats the preservative as a licence to relax technique; both treat it as a margin.

What Sets the Beyond-Use Window

Two separate clocks run on a reconstituted vial. The microbiological clock is governed by the preservative and by how many times the container has been entered; the widely applied institutional convention for an entered multiple-dose vial is a 28-day beyond-use date unless the manufacturer specifies otherwise. The chemical clock is governed by the solute, in this context, the peptide, and by temperature, light exposure, pH and the preservative’s own interaction with the dissolved molecule. The two clocks are independent, and the shorter one governs.

What the Preservative Does to the Solute

This is the part most often left out. Benzyl alcohol is a small alcohol at roughly 1% in solution, and small alcohols destabilise folded structure. In the pharmaceutical formulation literature this is a well-documented, quantified effect rather than a theoretical concern, and it is the reason preservative selection is a formulation decision rather than a default.

Hutchings and colleagues (2013, PMC3990441) compared five commonly used antimicrobial preservatives and ranked them by aggregation potential, finding m-cresol most aggregation-promoting, followed by phenol, then benzyl alcohol, then phenoxyethanol, with chlorobutanol least problematic. All five enhanced partial unfolding of a local region the authors identified as an aggregation “hot spot”, and stabilising that region reduced aggregation induced by every preservative tested. Benzyl alcohol, in other words, sits in the middle of the range: real, measurable, not the worst option available.

Research Evidence

In Vitro Evidence on Preservative-Induced Unfolding

The mechanism has been examined in several model proteins. Work on recombinant human interleukin-1 receptor antagonist (PMID 15514986) characterised benzyl alcohol-induced aggregation in aqueous solution and attributed it to a partially unfolded intermediate rather than direct chemical modification. Subsequent work on interferon alpha-2a (PMID 24974985) reported that the rank order in which preservatives induce protein aggregation was independent of the protein studied, which is a useful generalisation: the ordering appears to be a property of the excipients rather than of any one solute.

Broader reviews of protein and peptide instability (PMC9699111) place preservative-induced aggregation alongside the other major degradation routes, deamidation of asparagine and glutamine residues, oxidation of methionine, cysteine and tryptophan, disulphide scrambling, hydrolysis and physical aggregation. For a research peptide in solution, these pathways are what “degradation” actually means in practice.

Peptide-Specific Evidence in Multi-Dose Formulations

Peptides are not simply small proteins for these purposes, and a study specifically examining peptide-preservative interactions in aqueous multi-dose formulations (PMID 25893328) reported effects running in both directions: preservatives altered peptide self-interaction behaviour, and the peptide in turn affected the antimicrobial efficiency of the preservative. That second finding deserves emphasis, because it undercuts the assumption that a preserved diluent delivers a fixed antimicrobial performance regardless of what is dissolved in it.

More recent work on the molecular mechanism of antimicrobial excipient-induced aggregation in parenteral peptide formulations (PMID 35917158) has pushed toward a structural account of which peptide sequences are vulnerable. The practical implication for a laboratory is that compatibility is a per-compound question, and that a stability observation made on one peptide in benzyl alcohol does not transfer automatically to another.

Human Evidence on Benzyl Alcohol Toxicity

The neonatal restriction on benzyl alcohol is not precautionary boilerplate. Gershanik and colleagues described the gasping syndrome and benzyl alcohol poisoning in the New England Journal of Medicine in 1982 (PMID 7133084), linking a pattern of metabolic acidosis, gasping respiration, neurological deterioration and death in premature infants to benzyl alcohol exposure from preserved flush solutions in neonatal intensive care.

Neonatal metabolism of benzyl alcohol to benzoic acid and then to hippuric acid is immature, and cumulative exposure from small-volume flushes was sufficient to produce toxicity. Marketed bacteriostatic water labelling accordingly carries an unambiguous “NOT FOR USE IN NEONATES” warning, and the European Medicines Agency has published questions and answers on benzyl alcohol addressing labelling for the excipient in medicinal products. Any laboratory handling preserved diluents should be able to state this restriction without prompting.

What Remains Unknown

Three gaps recur. First, published compatibility data for benzyl alcohol against the specific research peptides most often reconstituted in it are sparse; most of the formulation literature concerns licensed biologics with commercial stability programmes behind them. Second, the interaction between preservative and peptide is bidirectional and dependent on concentration, so preservative efficacy in a peptide-containing solution is not reliably predictable from the preservative concentration alone. Third, real-world beyond-use conventions for reconstituted research peptides are inherited from institutional pharmacy practice rather than derived from stability-indicating assays on those peptides. Where a laboratory needs a defensible expiry, the answer is a stability study, not a convention.

Comparison: Bacteriostatic Water, Sterile Water and Sodium Chloride Injection

The choice between them follows from the study design rather than from convenience. A single-entry preparation for immediate analysis has no need of a preservative and gains a destabilising excipient by using one; sterile water is the cleaner vehicle. A vial that will be entered repeatedly over a fortnight needs the preservative. Where a peptide’s solubility or stability is known to be sensitive to ionic strength, sodium chloride injection introduces a variable that water does not.

Reconstitution and Handling of Lyophilised Peptides

A lyophilised peptide is a freeze-dried cake, often only one to fifty milligrams in a vial under partial vacuum. Everything about how it is brought into solution affects the concentration accuracy and the physical state of the resulting solution.

Concentration Arithmetic

Concentration is simply peptide mass divided by diluent volume. The vial mass is fixed by the supplier; the concentration is chosen by the operator through the volume added. The table below works this through for common vial masses. It is presented as bench arithmetic for preparing laboratory solutions of known concentration, not as any form of dosing guidance.

Two practical constraints bound the choice. A concentration high enough to approach saturation risks precipitation. A concentration low enough that the intended aliquot becomes a sub-microlitre volume is unmeasurable with ordinary laboratory syringes, and the resulting error swamps whatever effect is being studied. The workable range for most bench work sits between roughly 0.5 and 10 mg/mL.

Mechanics of Dissolution

The physical technique is unglamorous and matters. The septum is disinfected with 70% isopropyl alcohol and allowed to dry, since the alcohol does its work during evaporation rather than on contact; a pilot study on alcohol swabbing of vials (PMC12446881) is a reminder that swabbing practice is variable and consequential. The needle enters at an angle to reduce the chance of coring a fragment of the septum into the vial.

Diluent is introduced slowly and down the inner wall of the vial not jetted directly onto the lyophilised cake. A stream striking the cake generates local shear and an air-liquid interface, and peptides denature readily at interfaces. Once the diluent is in, the vial is swirled or rolled gently, never shaken. Shaking generates foam, and foam is a very large air-liquid interface; the visible froth is a proxy for the surface area at which aggregation is being nucleated. Dissolution of a small cake is typically complete within a minute or two of gentle agitation, and warming or vortexing to hurry it along is a false economy.

The reconstituted solution is then inspected against light: it should be clear and free of visible particulates, strands or haze. Cloudiness after full dissolution time has elapsed indicates precipitation or aggregation, and the correct response is to document it and set the vial aside, not to warm it until it clears. For laboratories sourcing lyophilised material to reconstitute this way, a single-compound listing such as the BPC-157 entry at a research supplier like NextGenPeps is handled on exactly these terms, cake mass declared on the label, diluent volume chosen by the operator, and the resulting concentration recorded rather than assumed.

Storage and Beyond-Use Dating

Lyophilised peptide in an unopened vial is comparatively robust and is generally held refrigerated or frozen, protected from light. Once reconstituted, the solution is the fragile form. Refrigeration at 2–8 °C is standard; the peptide-containing solution should be protected from light and from repeated temperature cycling.

Freeze-thaw cycling of a reconstituted solution is a recognised aggregation stressor, which is the argument for aliquoting into single-use portions at the point of reconstitution rather than repeatedly thawing one vial. Where a laboratory records a beyond-use date, the defensible practice is to record both clocks, date of reconstitution, number of entries, and the diluent lot alongside the peptide lot, so that a later stability question is answerable from the record rather than from memory.

Common Errors

• Treating the preservative as a disinfectant. Benzyl alcohol does not sterilise a septum, rescue a cored vial, or compensate for a reused needle.
• Shaking to dissolve. Fast, visible, and the most reliable way to aggregate a peptide before the first measurement.
• Jetting diluent onto the cake. Localised shear and interfacial stress at the moment of highest peptide concentration.
• Recording volume instead of concentration. A note reading “1 mL added” is uninterpretable without the vial mass; the record should carry mg/mL.
• Using a preserved diluent where the preservative is the wrong variable. For a single-entry analytical preparation, benzyl alcohol is an added destabiliser with no compensating benefit.
• Unlabelled vials. A reconstituted vial without compound, concentration, diluent, lot and date is unusable data.
• Ignoring the neonatal contraindication in shared clinical spaces. Preserved and unpreserved water vials look nearly identical; stocking them together invites substitution.

Is Bacteriostatic Water FDA Approved?

Bacteriostatic Water for Injection, USP is a marketed, prescription-status pharmaceutical product in the United States with approved labelling; DailyMed hosts the current label. That approval covers its use as a diluent or vehicle for other parenteral preparations, subject to the tonicity and neonatal warnings on the label.

What that approval does not do is extend to whatever is dissolved in it. The research peptides most often reconstituted in bacteriostatic water are not approved drugs, and several are explicitly discussed in the FDA’s compounding materials. The agency’s list of certain bulk drug substances for use in compounding that may present significant safety risks records nominated substances, including several research peptides, with stated concerns about immunogenicity for certain routes of administration, peptide-related impurities and active pharmaceutical ingredient characterisation. Approved diluent plus unapproved solute yields an unapproved preparation, and the regulatory status of a peptide study does not improve because the water in the vial has a monograph. Suppliers that list peptides alongside diluents, a GLOW peptide listing being one example, offer both categories on research-use-only terms, and the distinction between an approved excipient and an unapproved solute is worth keeping explicit in laboratory records.

Where to Source Bacteriostatic Water and Research-Grade Peptides

Diluent sourcing is usually treated as an afterthought and should not be. The diluent is present in every measurement made downstream, and a diluent of unknown provenance is an uncontrolled variable in every result.

What a documented diluent looks like:

• A named manufacturer and a USP designation on the label. “Bacteriostatic Water for Injection, USP” is a monograph claim, and the label should state the benzyl alcohol concentration.
• A visible lot number and expiry recorded in the laboratory notebook alongside the peptide lot.
• Intact packaging and an undisturbed flip-top seal on arrival.
• A container format matched to the workflow a multiple-dose vial where repeated entry is planned, and an unpreserved single-dose presentation where it is not.

What a documented peptide supplier looks like:

• A lot-matched certificate of analysis tied to the specific lot shipped rather than to a representative batch.
• Third-party HPLC purity data with a named laboratory and a test date, not an unattributed chromatogram image.
• Mass spectrometry confirming identity since purity without identity confirmation says nothing about whether the correct sequence is in the vial.
• A declared peptide content or net peptide mass distinct from gross vial fill weight.
• Explicit research-use-only labelling and no dosing guidance, protocol suggestions or human-use framing anywhere in the listing.

Red flags are mostly absences. A certificate with no laboratory name, no date or no lot reference is decoration. A supplier that will not produce documentation for the lot in hand has told you something. Listings that pair a research peptide with a suggested human protocol are making a regulatory claim they cannot support. And a diluent sold without a manufacturer, a USP designation or a stated preservative concentration should not enter a study at all. Among catalogues that list bacteriostatic water alongside lyophilised research compounds, the test is the same as for any other consumable: the label states what is in it, the lot is traceable, and the documentation arrives without being chased.

Frequently Asked Questions

What is the difference between bacteriostatic water and sterile water for injection?

Bacteriostatic water contains benzyl alcohol as a preservative and is supplied in multiple-dose vials; sterile water for injection contains no additives and is typically single-dose. The preservative is what makes repeated entry into the same container defensible. Both are hypotonic and both require a solute before any isotonic preparation.

Why does bacteriostatic water contain benzyl alcohol specifically?

Benzyl alcohol has a long formulation history in injectables, is miscible with water, and is effective as a bacteriostat at roughly 1%. In comparative studies of preservative-induced protein aggregation it also sits mid-range rather than at the destabilising end, behind m-cresol and phenol, which is a relevant consideration when a protein or peptide is the solute.

Is bacteriostatic water sterile?

The product is sterile as supplied. “Bacteriostatic” refers to the preservative’s ability to inhibit microbial growth after the container is entered, which is a different property. Neither attribute survives poor technique at the septum.

Can bacteriostatic water be injected on its own?

Marketed labelling states that it must be made approximately isotonic prior to use and warns that intravenous administration without a solute may result in haemolysis. It is labelled as a diluent and vehicle, not as a fluid to be given undiluted.

Why is bacteriostatic water contraindicated in neonates?

Benzyl alcohol accumulation caused documented poisoning in premature infants, described by Gershanik and colleagues in 1982, with metabolic acidosis and gasping respiration among the features. Neonatal metabolism of benzyl alcohol is immature, and cumulative exposure from small-volume flushes proved sufficient to cause harm. Current labelling carries an explicit warning against neonatal use.

Does benzyl alcohol damage peptides?

It can destabilise them. The formulation literature documents preservative-induced partial unfolding and aggregation across multiple model proteins and peptides, with benzyl alcohol reliably producing a measurable effect. The magnitude is compound-specific, and published compatibility data for most research peptides are sparse, which is a reason to record the diluent used rather than assume indifference.

How long does a reconstituted peptide vial last?

Two independent clocks apply: a microbiological window governed by the preservative and by the number of entries, and a chemical window governed by the peptide’s own degradation kinetics under the storage conditions used. The shorter governs, and neither is reliably known for an arbitrary research peptide without a stability-indicating assay.

Why should the vial be swirled rather than shaken?

Shaking generates foam, and foam is a very large air-liquid interface. Peptides adsorb to and denature at interfaces, so the visible froth corresponds to the surface at which aggregation is being nucleated. Gentle swirling or rolling dissolves a small lyophilised cake within a minute or two without that penalty.

Does the choice of diluent volume change the amount of peptide present?

No. The mass in the vial is fixed by the supplier; the diluent volume determines only the concentration of the resulting solution. Adding more diluent produces a more dilute solution of the same total mass, which is why the laboratory record should carry mg/mL rather than a volume note.

Is bacteriostatic water regulated differently from the peptides reconstituted in it?

Yes, and the difference is substantial. Bacteriostatic Water for Injection, USP is a marketed pharmaceutical product with approved labelling. Research peptides are not approved drugs, and several appear in FDA compounding materials with stated concerns about immunogenicity, impurities and characterisation. An approved diluent does not confer status on an unapproved solute.

The Bottom Line

Bacteriostatic water is the most-handled and least-examined material in peptide research. It is a pharmacopoeial product with a defined composition, water for injection plus 0.9% or 1.1% benzyl alcohol, pH 5.7, a specific purpose as a multiple-dose diluent, a documented population contraindication in neonates, and a measurable destabilising effect on the proteins and peptides dissolved in it. None of those four facts is optional knowledge for a laboratory that uses it daily.

The practical discipline follows from the chemistry. Choose the preserved diluent when repeated entry is genuinely planned and the unpreserved one when it is not. Introduce it down the vial wall, swirl rather than shake, inspect the solution before use, and record concentration rather than volume. Log the diluent lot beside the peptide lot, because a stability question raised three weeks later is only answerable if both were written down. Treat the preservative as a margin against small contamination events, not as a substitute for the aseptic sequence at every entry.

The peptide literature is difficult enough to interpret without the diluent being an unrecorded variable.

By [AUTHOR NAME PLACEHOLDER], [CREDENTIALS PLACEHOLDER]. Fact-checked by [FACT-CHECKER NAME PLACEHOLDER].

Research Use Only Disclaimer

The compounds and materials discussed in this article are intended for laboratory research use only. They are not approved by the U.S. Food and Drug Administration or any comparable regulatory authority for the diagnosis, treatment, cure or prevention of any disease. Nothing in this article is medical, veterinary or pharmaceutical advice, and nothing in it should be interpreted as a dosing recommendation, a protocol for use in humans or animals, or a therapeutic claim of any kind.

Research peptides described here are not for human or veterinary use. Concentration arithmetic is presented solely as bench preparation of laboratory solutions of known concentration. Where findings from the published literature are described, they are reported as they appear in the cited in vitro or animal work and should not be extrapolated to human application. Bacteriostatic Water for Injection, USP contains benzyl alcohol and is contraindicated in neonates; readers with clinical questions about any pharmaceutical product should consult the current approved labelling and a qualified healthcare professional. Readers are responsible for compliance with all applicable laws, institutional review requirements and biosafety regulations in their jurisdiction.

Stay updated, free articles. Join our Telegram channel

Join